Complete the medication reconciliation for an adult kidney-transplant recipient receiving cyclosporine and letermovir.
Drop-down Cloze
Choose your responses, then check the answer.
Explanation
When letermovir is coadministered with cyclosporine in an adult transplant recipient, letermovir is reduced to 240 mg once daily; simvastatin is contraindicated with that combination; cyclosporine concentrations require frequent monitoring.
Quick answer Lock the cyclosporine-letermovir dose and interaction safeguards.
Why this is correct Cyclosporine increases letermovir exposure, and the combination can substantially increase certain statin concentrations. Medication reconciliation must connect dose selection, contraindications, and therapeutic drug monitoring.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
References
1DailyMed: PREVYMIS (letermovir)CMV prophylaxis after transplant, cyclosporine dose interaction, statin contraindication, and drug-level monitoring
Oncology, transplant, and biologic safety reviewVerify the indication, immune status, infection screen, interacting medicines, current organ findings, authorized action, and measurable follow-up.